Athersys - Stock Price History | ATHX

Historical daily share price chart and data for Athersys since 2021 adjusted for splits. The latest closing stock price for Athersys as of September 24, 2021 is 1.41.
  • The all-time high Athersys stock closing price was 8.50 on July 16, 2007.
  • The Athersys 52-week high stock price is 3.03, which is 114.9% above the current share price.
  • The Athersys 52-week low stock price is 1.35, which is 4.3% below the current share price.
  • The average Athersys stock price for the last 52 weeks is 1.77.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Athersys Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 2.1089 1.2400 3.9800 1.1700 1.7500 42.28%
2019 1.4732 1.4800 2.0300 1.1600 1.2300 -14.58%
2018 1.9521 1.8100 2.7900 1.3400 1.4400 -20.44%
2017 1.6273 1.5400 2.5500 1.0900 1.8100 18.30%
2016 1.9333 1.0100 2.6450 1.0000 1.5300 48.54%
2015 1.5402 1.6600 3.2700 0.9850 1.0300 -34.81%
2014 2.1274 2.9500 4.1800 1.1500 1.5800 -36.80%
2013 1.7352 1.1500 2.5000 1.1300 2.5000 135.85%
2012 1.4765 1.8600 2.1400 0.9510 1.0600 -38.73%
2011 2.3018 2.6200 3.0100 1.1800 1.7300 -29.96%
2010 2.9644 4.0400 4.0400 2.3766 2.4700 -40.19%
2009 1.0316 0.4700 5.5500 0.4700 4.1300 817.57%
2008 2.5442 4.9100 5.0000 0.3201 0.4501 -90.83%
2007 6.5556 5.2500 8.5000 3.9000 4.9100 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.324B $0.001B
Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71